The podcast delves into the United States' reliance on China for pharmaceuticals, exploring vulnerabilities in the supply chain and potential national security risks. It highlights China's growing dominance in key starting materials, active pharmaceutical ingredients, and clinical trials. Panelists discuss the fragility of the U.S. biotech industrial base, emphasizing its dependence on investor capital and the potential for a rapid collapse if financial incentives shift towards Chinese competitors. Potential solutions include incentivizing domestic manufacturing, streamlining FDA approval processes, and fostering collaboration with allied countries to de-risk their own supply chains. The discussion also touches on ethical concerns related to clinical trials in China and the need for stricter oversight of foreign trial data.
Part 1: Supply Chain Vulnerabilities U.S. Reliance on China for Amoxicillin and Medicine Ingredients
The Illusion of Diversity and the Geopolitical Risks in Amoxicillin Supply
Quality Gaps and Unknown Origins in Pharmaceutical Manufacturing
Part 2: Domestic Manufacturing Challenges The Decline of U.S. Amoxicillin Manufacturing and National Security Concerns
Preserving U.S. Pharmaceutical Manufacturing Capacity: Defining Domestic Manufacturing
Supporting Domestic Production of Critical Medicines as a National Security Priority
Part 3: De-risking Strategies Defining the Problem: De-risking Chemical Inputs from China
Prioritizing Supply Chains and Leveraging French Shoring for Everyday Medicines
Avoiding Unintended Consequences: Congress's Role in Tariff Policy and Procurement
Part 4: Biotech and Clinical Trials The Fragility of the U.S. Biotech Industrial Base and the Shift in Financial Incentives
Addressing Clinical Trial Migration: FDA Approval Speed and Small-Scale Manufacturing
Streamlining Approval Processes and Focusing on Generic Manufacturing
Requiring FDA Inspection of Foreign Trial Data and Its Economic Impact
FDA Resources for Inspections and the Role of Tariffs
Part 5: Policy and Procurement China's Strategic Asset and the Need for Industrial Policy
The Cost of Federal Procurement Agreements and Controlling Market Access
Strategic Tariffs and Smart Industrial Policies for Amoxicillin Production
Part 6: National Security and Global Exposure The U.S. as the Patient: Medical Readiness and National Security Problems
China's Patient Strategy: Moving Up the Pharmaceutical Value Chain
The Inconsistency of API Exposure Statistics and the Need for Clarity
Mischaracterizations of the Supply Chain and India's Reliance on China
Strategic Tariffs and Supporting Indian Manufacturers
Part 7: Regional Impact and Scaling Pharmaceutical Supply Chains and Economic Opportunity in Northeast Ohio
Short-Term Vulnerabilities and Long-Term Risks to American Leadership
On-shoring Essential Medicines and Working with Allies for Everyday Medications
Working with India to De-risk and the Biggest Barrier to Scaling Production
Safe, Affordable Medicines and the Amoxicillin Shortage of 2022-23
Federal Government's Role in Supporting Manufacturers and Preventing Shortages
Demand Increases and Payment Mechanisms in the Amoxicillin Shortage
Part 8: Military and Allied Cooperation The Decision Not to Invest in Chinese Biotech and Concerns About IP
Military's Dependence on Chinese Supply Chains and Battlefield Medicine
DoD's Role in Research and Procurement and Building Civilian Infrastructure
A Stratified List of Priority Drugs and a Unified Pharmaceutical Strategy
Working with Allies and Overcoming the Obsession with Cheap Stuff
Part 9: Innovation and Future Outlook China's Challenge to U.S. Leadership in Pharmaceutical Innovation
Reinforcing U.S. Leadership in Biomedicine Innovation
The Costs and Time Overruns of Clinical Trials in the U.S.
Increasing Clinical Trial Sites and Access to New Medicines
De-risking the U.S. Drug Supply Chain and Focusing on Chemical Precursors
Efforts to Engage and Domestic Manufacturers De-risking Supply Chains
FDA's Indispensable Role and the Impact of Staff Cuts
Manufacturing Quality Oversight and Accountability for Indian Manufacturers
Protecting American Patients and the Broader Economy
Successful Partnerships Between the Private and Public Sectors
Competition and Radical Steps Forward in Drug Development
The Importance of Keeping Patients Out of the Hospital
China's Adversarial Role and the Importance of American Leadership
China's Aggressive Pursuit of Leadership in Biopharmaceutical Development
Ensuring the U.S. Remains the Global Hub for Biopharmaceutical Innovation
Taking Away Unnecessary Blockades and Ethical Guidelines in Clinical Trials
Strengthening Pharmaceutical Innovation and Production at Home
Cuts to Scientific Research and the Goal of Being Less Dependent on China
The Importance of NIH Funding and U.S. Research Institutions
The Brain Drain and the Long-Term Competitiveness of Biomedical Innovation
Sign in to continue reading, translating and more.
Open full episode in Podwise 
